The U.S. Food and Drug Administration has approved roflumilast, an oral drug that reduces exacerbations from severe chronic obstructive pulmonary disease (COPD). Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244989.htm
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.